A Comment on the use of Levosimendan for the Management of Right Ventricular Dysfunction in Patients Undergoing Mitral Valve Surgery

Ann Card Anaesth. 2024 Jan 1;27(1):94-95. doi: 10.4103/aca.aca_86_23. Epub 2024 Jan 12.
No abstract available

Publication types

  • Letter

MeSH terms

  • Cardiotonic Agents* / therapeutic use
  • Humans
  • Hydrazones* / therapeutic use
  • Mitral Valve* / surgery
  • Pyridazines* / therapeutic use
  • Simendan* / therapeutic use
  • Ventricular Dysfunction, Right* / drug therapy

Substances

  • Simendan
  • Pyridazines
  • Hydrazones
  • Cardiotonic Agents